Eyevensys is a privately held, clinical-stage biotechnology company. Our first-in-class, non-viral vector gene therapy, sustained drug delivery system offers a new approach to treating major ophthalmic conditions. In particular, degenerative retinal diseases and retinal vascular diseases such as wet AMD and dry AMD. Together, these illnesses account for the vast majority of vision loss around the globe and significantly impact quality of life for patients of all ages.
Revolutionizing the Treatment of Eye Disease
The Eyevensys technology enables therapeutic proteins to be produced inside the eye—by the eye itself—providing long-lasting treatment effects. It works by administering DNA plasmids directly into the ciliary muscle in the eye, using a process called electrotransfection.
Eyevensys was founded in 2008 by Francine Behar-Cohen, MD, PhD, Professor of Ophthalmology at Paris Descartes University.
Our world-class team brings a wealth of knowledge in ophthalmic and rare disease drug discovery, and development experience spanning Big Pharma, biotech, academia, and nonprofit institutions.